First Group Of Heart Failure Patients Treated With "Off-The-Shelf" Adult Stem Cells Successfully Pass Key Safety Milestone
Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced successful achievement of the key safety milestone in the first low-dose cohort of patients treated with Revascor(tm), the proprietary allogeneic, or “off-the-shelf”, universal adult stem cell product for congestive heart failure. Safety data from all 20 congestive heart failure patients enrolled in the multi-centre Phase 2 clinical trial by Mesoblast’s United States-based sister company Angioblast Systems Inc.
[Read the full article here]Related News:
Mesoblast Announce Heart Muscle Function Improved After Single, Lowest-Dose Injection Of "Off-The-Shelf" Stem Cells In Patients With Heart Failure
Bioheart Launches First US FDA Approved Clinical Trial That Tests Gene-Modified Stem Cell Therapy In Patients With Congestive Heart Failure
Safety Phase Of Novel UM Stem Cell Trial Completed